Neisseria meningitidis is a major cause of meningitis and septicemia with cases, outbreaks, and epidemics reported globally in industrialized and non-industrialized countries.
vaccination strategies have been used. Recently, the rapid clonal expansion of meningococcal serogroup W (MenW) has been associated with a change in the national and regional vaccination recommendations from monovalent meningococcal serogroup C vaccines to meningococcal serogroup A, C, W, Y (MenACWY) vaccines in several countries. This review highlights these and other changes in IMD epidemiology and meningococcal vaccination recommendations, summarizes information available for currently available conjugate MenACWY vaccines, and focuses on clinical study data for the most recently approved MenACWY conjugate vaccine, MenACWY vaccine conjugated to tetanus toxoid (MenACWY-TT). MenACWY-TT studies spanned multiple age groups and generally demonstrated safety and immunogenicity in comparison with other meningococcal vaccines and under concomitant administration of other routine vaccines. Continuous updates to meningococcal vaccine recommendations in response to changing epidemiology, as have been undertaken for MenW, are necessary to ensure optimal population protection. Funding: Pfizer, Inc. 
INTRODUCTION
Invasive meningococcal disease (IMD) is a serious infection caused by the Gram-negative bacterium Neisseria meningitidis [1] . Some age groups are disproportionately affected by IMD, with major peaks of IMD incidence occurring in infants and in adolescents and young adults [2] [3] [4] . Adolescents and young adults typically exhibit lifestyles that are thought to promote meningococcal transmission, such as being exposed to smoke; frequent attendance at pubs, bars, and nightclubs; living in close quarters; and intimate kissing with multiple partners [5, 6] . IMD rates are markedly elevated among students in universities relative to other settings [2, 7] , and outbreaks or clusters of disease within the university setting can occur [8] [9] [10] . Overall incidence of IMD is generally low but varies by country/region [2, 3] . Nevertheless, outbreaks are unpredictable [11] , and sporadic individual cases continue to occur in both industrialized and non-industrialized countries [12] .
Neisseria meningitidis is categorized into 12 serogroups according to the biochemical composition of the bacterial capsular polysaccharide [13] . However, only five serogroups (A, B, C, W, and Y) are responsible for the majority of disease worldwide [14] ; vaccines for the prevention of IMD caused by each of these serogroups are available. Currently licensed meningococcal serogroup A, C, W, Y (MenACWY) conjugate vaccines include MenACWY-CRM 197 (Menveo Ò ; GlaxoSmithKline, Rixensart, Belgium), which is conjugated to the diphtheria protein cross-reactive material 197 (CRM 197 ) [15] ; MenACWY-D (Menactra Ò ; Sanofi Pasteur, Swiftwater, PA, USA), which is conjugated to diphtheria toxoid (D) [16] ; and MenACWY-TT (Nimenrix Ò ; Pfizer Inc, Sandwich, UK), which is conjugated to tetanus toxoid (TT) [17] . Available monovalent meningococcal serogroup C (MenC) vaccines include MenC-CRM 197 (Menjugate Ò ; GlaxoSmithKline Vaccines Srl, Siena, Italy) [18] and MenC-TT (NeisVac-C TM ; Pfizer Ltd, Kent, UK) [19] , which use CRM 197 and TT, respectively, as carrier proteins. In addition, PsA-TT (MenAfriVac TM ; Serum Institute of India, Pune, India) is a meningococcal serogroup A (MenA) conjugate vaccine using TT as a carrier protein that was developed specifically to combat MenA disease in Africa [20] . Hib-MenC-TT (Menitorix Ò ; GlaxoSmithKline, Rixensart, Belgium) is a combination vaccine that includes MenC in addition to Haemophilus influenzae type b (Hib) [21] . The use of these polysaccharide conjugate meningococcal vaccines has collectively reduced the burden of meningococcal disease worldwide [22, 23] .
Due to the poor immunogenicity of serogroup B capsular polysaccharide [24] [25] [26] [28] . MenB-FHbp is composed of two recombinant lipidated factor H binding proteins (FHbp), one variant each from subfamilies A and B. MenB-4C contains neisserial adhesin A, neisserial heparin-binding antigen, and a nonlipidated FHbp variant from subfamily B, in addition to outer membrane vesicles [28] . Vaccines for the prevention of MenB disease may provide some cross-protection against strains from other serogroups, including meningococcal serogroup X (MenX) [29, 30] , which emerged recently in Africa [31] .
Based on the rapid and severe clinical presentation of IMD, relative ease of transmission via respiratory secretions, and unpredictability of IMD incidence and epidemiology, protection can best be achieved by initiating proactive rather than reactive vaccination strategies [32] . Herd protection (i.e., protection of unvaccinated individuals) can be an important component of vaccination-mediated disease control, which occurs by limiting bacterial acquisition and thus transmission from vaccinated to unvaccinated individuals; this phenomenon has been particularly evident for certain MenC vaccination programs (i.e., in the Netherlands, United Kingdom, and Australia) [33] [34] [35] . Evidence also exists of reduced meningococcal carriage associated with MenA vaccine use in Africa [36] . Optimized vaccination strategies require continual adaptation to include available vaccines and thus ensure protection against emerging diseasecausing strains.
This article details recent changes in IMD epidemiology, the associated shifts in meningococcal vaccination recommendations, and data from clinical studies of MenACWY-TT, the most recently approved MenACWY vaccine [17] . Other MenACWY conjugate vaccines that were licensed earlier (MenACWY-D and MenACWY-CRM 197 ) [15, 16] are also briefly summarized; their use has been previously described in detail [37] . Additionally, although many regions have multiple MenACWY vaccines licensed, some vaccination programs only use MenACWY-TT [38] [39] [40] . This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Recent Changes in Meningococcal Epidemiology and Vaccination Recommendations
Global shifts in meningococcal epidemiology coupled with a growing body of data regarding MenACWY vaccines have prompted changes in meningococcal vaccine recommendations in various countries (Table 1) [38, 39, . Epidemiologic shifts and any associated changes in recommendations are summarized for select countries below.
The United Kingdom
The United Kingdom has been experiencing a pronounced increase in meningococcal serogroup W (MenW) disease since 2010 [70] , with the number of reported MenW cases in England increasing more than tenfold from 2009-2010 (22 cases) to 2016-2017 (225 cases) [41] . Adults C 45 years old were the primary age group initially affected, but over time, MenW IMD increased in all age groups. Genetic analysis demonstrated that a majority of the MenW isolates responsible for the initial rapid increase belonged to a single clone of clonal complex 11 (cc11) [70] .
Due to this rapid increase in MenW IMD, in September 2015 MenACWY vaccination or MenACWY-TT) replaced the previous recommendation for monovalent MenC vaccination for adolescents [42] . The new vaccination program was directed at adolescents in school year 9, with the strategy of reducing transmission by targeting the age group preceding that in which meningococcal carriage rates begin to drastically increase [42, 71] . Public Health England reported vaccination coverage rates of 71.4-83.6% by August 2017 [72] . The program also included catch-up vaccination for students 14-18 years of age as well as those \ 25 years of age who were entering university [42] . MenACWY vaccination coverage in England among students who left school in 2015-2016 was 36.6% by June 2016 [73] . During the first year of the program, the number of MenW cases in school leavers decreased by 69%, with 6 confirmed cases (all unvaccinated) versus 19.4 predicted cases [73] .
France
MenW disease has increased in France, beginning in 2015, and accounted for 9% of all IMD notifications in 2016, with an incidence rate of 0.07 per 100,000 [43] . Compared with cases from other serogroups, older individuals had a higher incidence of MenW IMD and exhibited a higher case-fatality rate. As in the United Kingdom [70] , multilocus sequence typing revealed that the MenW cases responsible for the upsurge in France were dominated by cc11; this was in contrast to endemic MenW disease caused largely by cc22 [43] . The increase in MenW IMD in France includes a 2017 outbreak among French university students that involved two cases and one death [8] . To date, France continues to recommend only MenC vaccination to infants and toddlers [45] . Of note, the vaccine schedule in France was modified in 2016 to include a MenC dose at 5 months of age, in addition to a second dose at 12 months of age, due to the persistent burden of MenC disease [45, 74] .
Italy
Meningococcal epidemiology in Italy has demonstrated recent trends that differ from those of many other countries. In 2011, [61] . These recommendations were included in the 2017 Argentina vaccination calendar [62] .
Chile
The increase of MenW IMD in Chile occurred somewhat differently than in Argentina. In 2006, only 4.5% (3/67) of cases were caused by MenW [58] , increasing to 10.7% (6/56) in 2010 [59] . MenW disease incidence drastically increased thereafter, accounting for nearly three-quarters (73.1%; 87/119) of IMD in Chile in 2014 [60] . Proportions were high in most age groups in 2014, especially infants (65.8%) and individuals aged C 5 years (75-100%). By 2017, MenW had decreased to 58.8% (47/80) of isolates [63] . Similar to other global observations, a recently published study found that, among 119 IMD isolates collected in Chile, all MenW isolates (66%) were identified as cc11 [85] . As a result of increasing MenW prevalence, the Chilean Ministry of Health initiated a MenACWY vaccination program in 2012 targeting children aged C 9 months to \ 5 years, and a single MenACWY-TT dose at 12 months of age was added to the NIP in 2014 [39, 64, 69] . In the years that followed, the number of cases substantially decreased in the age groups targeted for vaccination, but no herd protection was observed, likely due to the age group vaccinated [39] .
MenACWY-D and MenACWY-CRM 197 Vaccines
Of the three currently [17, 89, 90] . Additionally, the ages for which the vaccines are licensed can vary both between vaccines and between countries for a particular vaccine.
MenACWY-D
MenACWY-D is available in several countries, including some of those experiencing recent MenW disease increases, such as Australia, Canada, Argentina, and Chile [89] . Ages for which the vaccine is approved differ by country. For instance, in Canada, it is approved for use in individuals 9 months to 55 years of age [91] . For children 9-23 months of age, the manufacturer recommends that MenACWY-D be administered in two doses given at least 3 months apart. [16] . The immunogenicity of MenACWY-D has been described previously, with reports of C 86.4% of subjects 1 year of age having serum bactericidal assays using human complement (hSBA) titers C 1:8 for each of the four serogroups 1 month after a second dose [91] . Additionally, C 96.2% of children 2--10 years of age had SBA titers C 1:8 across the four vaccine serogroups 28 days after vaccination. Commonly reported reactions following MenACWY-D administration include injection site tenderness or pain and irritability in children and injection site pain, headache, and fatigue in adults.
MenACWY-CRM 197
Similar to MenACWY-D, MenACWY-CRM 197 is approved in many countries experiencing recent MenW disease increases, including the United Kingdom, France, Netherlands, Australia, Canada, Argentina, and Chile, among others [90] . In the European Union, MenACWY-CRM 197 is approved for individuals 2 years and older, who are given a single dose [92] . In the United States, on the other hand, the vaccine is approved from 2 months of age, with recommended dosing for infants varying by age at initiation [15] . A booster dose can be given according to recommendations in both regions [15, 92] . In children 2-10 years of age, C 68% had hSBA titers C 1:8 across the four serogroups at 1 month after a single dose; percentages were C 75% in adolescents 11-18 years of age and C 69% in adults 19-55 years of age [92] . Commonly reported reactions after MenACWY-CRM 197 dosing include pain, firmness, and erythema at the injection site and sleepiness, headache, irritability, and generally feeling unwell in children; and pain, firmness, and erythema at the injection site and nausea, headache, myalgia, and generally feeling unwell in adolescents and adults.
Review of Recent MenACWY-TT Studies
The recommendations for MenACWY vaccination in most of the reviewed countries include the most recently approved quadrivalent vaccine, MenACWY-TT [17, 39, 40, 42, 93] . MenACWY-TT is licensed throughout a large part of the lifespan (i.e., 6 weeks of age and older) [17, 86] . Several studies conducted in infants, toddlers, children, and adolescents have supported the expanded recommendations for MenACWY-TT vaccine use; these are summarized below and in Table 2 [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] .
Infant Studies
In a noninferiority study conducted in Europe, 2095 infants were randomized to receive MenACWY-TT at 2, 3, 4, and 12 months of age; MenACWY-TT at 2, 4, and 12 months of age; MenC-CRM 197 at 2, 4, and 12 months of age; or MenC-TT at 2, 4, and 12 months of age [94] . All subjects received other routine vaccinations as recommended. Immunogenicity was assessed 1 month after the primary infant series. A 2-or 3-dose primary series of MenACWY-TT was shown to be noninferior to a 2-dose primary series of MenC-CRM 197 or MenC-TT in terms of the immune response to MenC. One month after primary vaccination, C 93.1% of subjects had titers C 1:8 in serum bactericidal assays using rabbit complement (rSBA) for the four serogroups, whereas C 88.5% had titers C 1:8 in assays using hSBA. Although proportions of subjects with titers C 1:8 decreased by 12 months of age, immune responses to booster doses were robust, with C 99.1% of subjects having rSBA or hSBA titers C 1:8 a month after booster vaccination. MenACWY-TT vaccination was also demonstrated to be safe and tolerable.
In another study, MenACWY-TT was administered to 750 infants in a 2:1:1 randomization ratio with dosing at 2, 4, 6, and 15-18 months of age; 6 and 15-18 months of age; or 15-18 months of age [95] . All infants also received additional routine vaccinations. Efficacy and safety measures were reported. Among those receiving a 3-dose primary series at 2, 4, and 6 months of age, C 99.4% of subjects had rSBA titers C 1:8 for each of the No SAEs related to vaccination were reported from 6 months following primary vaccination through to the year 5 visit [97] . At 1 month postvaccination, C 92.8% of toddlers vaccinated with MenACWY-TT had rSBA titers C 1:8 for the four serogroups, and geometric mean titers (GMTs) increased substantially compared with titers before vaccination. Responses were robust and slightly higher after two doses compared with one dose. Coadministration of MenACWY-TT and PCV13 did not alter the safety or immunogenicity profile of MenACWY-TT.
Child Studies
In a phase 2 study, 309 children aged 2-10 years in Finland were randomized 3:1 to receive one dose of MenACWY-TT or a licensed meningococcal MenACWY polysaccharide vaccine (Men-PS) [98] . The study assessed vaccine response rates, which were defined as a postvaccination rSBA titer C 1:32 for seronegative children (rSBA titer \ 1:8 at prevaccination) and C fourfold increase in rSBA titer from prevaccination to postvaccination for seropositive children (rSBA titer C 1:8 at prevaccination). At 1 month postvaccination, MenACWY-TT was noninferior to Men-PS with rSBA response rates C 94.3% in the MenACWY-TT group and C 81.2% in the Men-PS group. Exploratory analyses demonstrated that response rates and rSBA GMTs were higher among MenACWY-TT than Men-PS recipients, and a higher percentage of subjects had rSBA titers C 1:128 for serogroup C in the MenACWY-TT group versus the Men-PS group. In the MenACWY-TT and Men-PS groups, pain was the most frequent solicited local symptom in children aged 2-5 years (45.1% and 71.8%, respectively) and 6-10 years (71.8% and 82.1%, respectively); redness and swelling were more common in the MenACWY-TT groups [98] .
A follow-up study evaluated the persistence of serum bactericidal antibodies in these subjects up to 5 years after receiving MenACWY-TT or Men-PS [99] . At year 5, the proportion of subjects in the MenACWY-TT group (n = 98) with rSBA titers C 1:8 for serogroups A, C, W and Y were 90.8%, 90.8%, 78.6%, and 78.6%, respectively; in the Men-PS group (n = 13), these proportions were 15.4%, 100%, 0.0%, and 7.7%, respectively. Exploratory analyses indicated that differences between the vaccine groups were significant for serogroups A, W, and Y. As individuals with rSBA-MenC titers \ 1:8 at any time during the study were revaccinated with a MenC conjugate vaccine and withdrawn from further analyses, interpretation of serogroup C antibody persistence in the remaining subjects was difficult.
Adolescent and Young Adult Studies
A study of 93 British adolescents 16-19 years of age who had been previously vaccinated with MenC-TT or MenC-CRM 197 at 3.5-5.9 years of age compared immunogenicity and safety of MenACWY-TT with MenACWY-CRM 197 [100] . Of the 92 participants with available data, nearly all had protective rSBA titers (i.e., C 1:8) for all serogroups at 1 month after booster in both groups, with the exception being for serogroup Y in one subject boosted with MenACWY-CRM 197 . The highest titers were measured in subjects primed with MenC-TT and boosted with MenACWY-TT. A high proportion of subjects in both MenACWY booster groups had protective titers through 9 months after booster. Both vaccines were well tolerated, although redness and muscle pain were comparatively more common among MenACWY-CRM 197 recipients, and tiredness was more common among MenACWY-TT recipients. No vaccine-related SAEs occurred in either group.
A similar study assessed MenACWY-TT boosting in 501 Dutch adolescents aged 10, 12, and 15 years who had previously received the MenC vaccine at 14 months to 3 years of age [102] . All children had been primed with MenC-TT, and booster vaccinations used either MenACWY-TT or MenC-TT. One month after booster dosing, all participants except one had rSBA titers C 1:8 for serogroup C; however, noninferiority for MenACWY-TT compared with MenC-TT could not be demonstrated for the subjects in the 10-and 15-year-old age groups. rSBA GMTs significantly declined in all age groups by 1 year after booster dosing, and noninferiority could not be demonstrated for any age group; however, all but two participants maintained rSBA titers C 1:8. Importantly, the decline in protective antibodies was fastest in the 10-year-old age group, which may be important in determining optimal ages for vaccination.
Results from this study for serogroups A, W, and Y were reported in a separate publication and indicated that GMTs significantly increased at 1 month after MenACWY-TT vaccination [101] . MenW and MenY GMTs were higher in the 15-year-old age group compared with the 10-year-old age group, and MenA and MenY GMTs were higher in the 12-year-old age group compared with the 10-year-old age group; 100% of subjects in the 12-and 15-year-old age groups and C 94.5% in the 10-year-old age group achieved rSBA titers C 1:8 for all three serogroups. At 1 year after booster, 95.1% of subjects maintained rSBA titers C 1:8 against all three serogroups, and MenW GMTs in the 10-year-old age group were significantly lower than in the other age groups, again suggesting that vaccination after earlier adolescence might maximize effectiveness.
The safety and immunogenicity of MenACWY-TT were compared with that of MenACWY-D in Canadian and US adolescents and young adults in a phase 2 clinical study [103] . Subjects were randomized to receive a single dose of MenACWY-TT (1 of 2 lots, with lot A and lot B having 68% and 92% O-acetylation of the MenA polysaccharide, respectively) or MenACWY-D. Vaccine response was defined as an hSBA titer C 1:8 in initially seronegative subjects or a fourfold increase in titer in subjects who were initially seropositive. At 1 month after vaccination, vaccine response rates for the four serogroups ranged from 51.2 to 77.2% in subjects vaccinated with MenACWY-TT lot A, 51.0-82.5% in subjects vaccinated with MenACWY-TT lot B, and 39.0-76.3% in subjects vaccinated with MenACWY-D. The primary study objective, noninferiority of MenACWY-TT (lot A) compared to MenACWY-D with respect to hSBA responses against each serogroup, was demonstrated. Local and systemic events were comparable among the three vaccine groups, and the frequency of SAEs was similar in MenACWY-TT and MenACWY-D vaccinated subjects.
The persistence of the bactericidal antibody response was compared in US subjects who had been randomized 3:1 to receive one dose of MenACWY-TT or MenACWY-D at 10-25 years of age [105] . Five years postvaccination, the proportions of subjects with hSBA titers C 1:8 against serogroups A, C, W, and Y were 48.9%, 92.9%, 87.0%, and 94.4%, respectively, in the MenACWY-TT group and 44.4%, 79.5%, 84.1%, and 90.9% in the MenACWY-D group. In the MenACWY-TT group, serogroup C, W, and Y hSBA GMTs remained above prevaccination levels at 5 years; in the MenACWY-D group, serogroup W and Y GMTs remained elevated. Exploratory analyses suggested that serogroup C and Y GMTs and the percentage of subjects with titers C 1:8 against serogroup C were higher in the MenACWY-TT group compared with the MenACWY-D group. No vaccination-related SAEs were reported during the 5 years of this study.
A study carried out in the Philippines and Saudi Arabia evaluated bactericidal antibody persistence and safety of MenACWY-TT in healthy adolescents and adults aged 11-55 years at the time of vaccination [104] . Of the 500 subjects who were randomized 3:1 to receive one dose of MenACWY-TT or Men-PS, 404 vaccinated subjects returned at year 5: 299 subjects in the MenACWY-TT group (including n = 208 subjects aged 11-17 years) and 105 subjects in the Men-PS group (including n = 76 subjects aged 11-17 years). In the total year 5 cohort, the percentages of subjects with rSBA titers C 1:8 for serogroups A, C, W, and Y in the MenACWY-TT group were 90.0%, 79.3%, 71.6%, and 84.3%, respectively; corresponding values in the Men-PS group were 74.3%, 71.2%, 24.8%, and 44.8%, respectively. Exploratory analyses indicated that the percentages of subjects with rSBA titers C 1:8 for serogroups A, W, and Y were significantly higher in the MenACWY-TT group than the Men-PS group at year 5. In both vaccine groups, rSBA antibody responses of the adolescent age group were consistent with those of the total population. No SAEs related to vaccination were reported during the 5-year study period.
Two recent studies addressed concomitant administration of MenACWY-TT with other vaccines commonly recommended to adolescents [106, 107] . In reviewing these studies, it is important to note that vaccination rates among adolescents are often low [73, 108, 109] , and concomitant vaccination is an established strategy for increasing vaccine uptake [110, 111] . The first study compared concomitant administration of MenACWY-TT and tetanus, diphtheria, and acellular pertussis vaccine (Tdap; Boostrix Ò ; GlaxoSmithKline, Rixensart, Belgium) [112] with sequential administration of the two vaccines in 691 adolescents aged 11-25 years from Korea, Germany, and the Dominican Republic. One month after vaccination, prespecified noninferiority criteria were met in the coadministration group for all four meningococcal serogroups (using rSBA GMTs) as well as for antibodies targeting diphtheria and tetanus but not for antibodies targeting pertussis antigens. Overall, 96.9-100% of subjects had anti-meningococcal rSBA titers or antiTdap antibody concentrations meeting or exceeding assay cutoffs for all serogroups and antigens tested. Coadministration did not increase frequencies of local reactions, systemic events, or unsolicited AEs, and none of the three SAEs reported across groups were considered vaccine-related.
An additional study in 1300 female subjects aged 9-25 years in Estonia, Thailand, and the Dominican Republic investigated concomitant administration of MenACWY-TT with 2-valent human papillomavirus (HPV2; Cervarix TM ; GlaxoSmithKline, Rixensart, Belgium) [113] and Tdap vaccines [107] . Concomitant vaccination of MenACWY-TT and HPV2 with one another or with Tdap in addition was noninferior to individual administration of either vaccine. Across groups, C 97.3% of subjects had rSBA titers C 1:8 or C 1:128 against each of the meningococcal serogroups, and C 99.6% of subjects in each group had anti-HPV antibodies meeting or exceeding prespecified thresholds. Similar to the study assessing concomitant administration with Tdap, coadministration of all three vaccines met noninferiority criteria for diphtheria and tetanus but not pertussis antigens compared with coadministration of Tdap with HPV2 only; however, C 98.0% of subjects in each group had pertussis antigen antibodies above the assay cutoff. Safety and tolerability of all vaccines were not affected by concomitant administration.
DISCUSSION
Vaccination is the best method for preventing IMD [37] . Coupled with the broad distribution of A, C, W, and Y IMD serogroups worldwide and the potential for sporadic and unpredictable outbreaks, multivalent meningococcal vaccines provide the best prophylactic coverage against IMD. Several countries (United Kingdom, France, the Netherlands, Australia, and Chile) that included monovalent MenC in their national meningococcal vaccination recommendations have experienced recent notable increases in IMD due to MenW [41, 43, 47, 51, 59] . Recent global increases in MenW disease and resulting changes in vaccination programs are of critical importance and have been chronicled elsewhere in addition to the current review [114] . Increases were sometimes quite dramatic, such as the tenfold increase in MenW IMD in the United Kingdom that occurred from 2009-2010 to 2016-2017 [41] . In association with increased incidence, the United Kingdom, the Netherlands, Australia, and Chile, as well as other countries and regions, have opted to update meningococcal vaccination recommendations to replace monovalent MenC vaccine with quadrivalent MenACWY vaccines [38, 42, 69, [75] [76] [77] [115] [116] [117] . To similarly address recent changes in IMD epidemiology, Italy changed its vaccination recommendations to include an adolescent MenACWY vaccine dose to address a MenC outbreak that occurred in 2015-2016 [44] [45] [46] 67] . In some cases, the effects of MenACWY vaccination are already evident (e.g., United Kingdom, which had a 69% decrease in the number of MenW cases in the first year of an emergency MenACWY vaccination program targeting matriculated high school students/college entrants) [73] . Epidemiologic surveillance over the coming years is expected to provide valuable insight into the protection afforded by broader serogroup coverage.
Currently, three conjugate quadrivalent vaccine formulations-MenACWY-CRM 197 , MenACWY-D, and MenACWY-TT-are in use globally [15] [16] [17] . Of these, MenACWY-TT is the most recently approved, with initial authorization in the European Union in 2012 [17] and approval in more than 40 other countries [88] . The TT carrier protein contained in the MenACWY-TT formulation provides good thermal stability and a large surface area for polysaccharide conjugation [118] . In addition, higher antibody titers postdosing have been reported with the TT protein than with the CRM protein [119] [120] [121] . The immunogenicity and safety profile of MenACWY-TT has been established in clinical studies and supports use across all age groups [17] . The European Medicines Agency license for MenACWY-TT currently specifies that infants 6 weeks to \ 6 months of age should be given two doses separated by 2 months, followed by a booster dose at 12 months of age with at least 2 months since the previous primary dose [17] . Infants from 6 months to \ 12 months of age should be given one dose, followed by a booster dose at 12 months of age or at least 2 months after the first dose. Toddlers from 12 months of age, children, adolescents, and adults are given a single dose; previously vaccinated individuals who are 12 months or older may be given a booster MenACWY-TT dose if previously vaccinated with a conjugated or plain polysaccharide meningococcal vaccine.
The available MenACWY conjugate vaccines induce protection against four of the five major disease-causing serogroups, the greatest number in a single vaccine. However, these vaccines will not prevent serogroup B infections, which are a predominant cause of IMD in many countries [23] . An adjunct vaccination strategy with recently introduced MenB vaccines should therefore be considered to provide protection against this serogroup. An innovative approach of combining these vaccines into a pentavalent entity is currently under evaluation. Two studies conducted in adolescents and young adults evaluated a pentavalent MenABCWY vaccine based on MenACWY-CRM 197 and MenB-4C compared with individual administration of both vaccines [122, 123] . Immune responses after two doses of the MenABCWY vaccine were high for all serogroups in both studies [122, 123] , and an extension study also supported prime-boost strategies in those vaccinated with currently licensed MenB-4C or MenACWY-CRM 197 vaccines [124] . Another MenABCWY vaccine based on MenB-FHbp for the serogroup B component is currently under clinical evaluation [125] .
The addition of subcapsular antigens to capsular polysaccharide-based multivalent vaccines could also augment protection against non-MenB isolates (cross-protection), as shown by the high proportions of MenB-FHbp recipients with hSBA titers C 1:8 against strains from serogroups C, W, X, and Y [30]. For MenB-4C, two studies suggested that sera from vaccinated subjects were capable of killing MenW and MenX strains [29, 126] .
Although direct protection is an important component of meningococcal vaccination strategies, reducing meningococcal carriage and transmission can also be crucial for reducing IMD on a population level. In addition to inducing protective antibodies, meningococcal conjugate vaccines have the ability to reduce acquisition of nasopharyngeal carriage in those vaccinated and thus reduce subsequent transmission to the unvaccinated [127] . Protection of unvaccinated individuals (herd protection) has been observed with MenC conjugate vaccination in the United Kingdom, where decreases in IMD incidence were first evident in vaccinated individuals, followed by unvaccinated children and older adults [34] . Similar findings were observed with the use of MenC vaccine in the Netherlands, where MenC IMD decreased rapidly in all age groups, although only children and adolescents B 18 years of age were vaccinated [33]; such outcomes were also observed in Australia [35] . As mentioned previously, data also indicate reduced carriage following MenA vaccination in Africa [36] . Supportive data are still needed to address the potential of MenACWY vaccines to induce herd protection.
CONCLUSION
In summary, global shifts in IMD epidemiology, particularly the increased incidence of MenW IMD, have resulted in reactive vaccination recommendations in several countries. Quadrivalent conjugate vaccines cover the greatest number of serogroups among available vaccines, and reductions in MenW IMD are already evident in the United Kingdom, where MenACWY vaccination has been incorporated into the immunization program [73] . As IMD occurs unpredictably, proactive vaccination strategies providing broad protection against disease-causing serogroups are advisable. MenACWY-TT, the most recently approved quadrivalent vaccine, administered as a primary infant series or as a single dose in toddlers and adolescents, provides broad seroprotection coupled with a favorable safety profile.
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